Cargando…

Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids

Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation. Aside to the potential psychotropic effects of ketamine, a Cochrane review reported that available studies suggest a modest effect of ketamine for chronic pain months to years after sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Bigman, Daniel, Kunaparaju, Sindhura, Bobrin, Bradford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747796/
https://www.ncbi.nlm.nih.gov/pubmed/29133582
http://dx.doi.org/10.1136/bcr-2017-222059
_version_ 1783289317211242496
author Bigman, Daniel
Kunaparaju, Sindhura
Bobrin, Bradford
author_facet Bigman, Daniel
Kunaparaju, Sindhura
Bobrin, Bradford
author_sort Bigman, Daniel
collection PubMed
description Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation. Aside to the potential psychotropic effects of ketamine, a Cochrane review reported that available studies suggest a modest effect of ketamine for chronic pain months to years after surgical intervention. We present a patient with acute suicidal ideation who required immediate inpatient psychiatric admission in the setting of concurrent chronic pain on cannabinoids which could not be prescribed within our inpatient hospital setting. This presented a clinical dilemma to rapidly reverse the patient’s suicidality while substituting the patient’s prescribed cannabinoid products with an alternative pain regimen. Since there is emerging support in the use of ketamine in suicidality and chronic pain, we administered ketamine while withholding cannabinoid products and found evidence to support its use in rapid reversal of suicidal ideation and temporary chronic pain relief.
format Online
Article
Text
id pubmed-5747796
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-57477962018-01-03 Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids Bigman, Daniel Kunaparaju, Sindhura Bobrin, Bradford BMJ Case Rep Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation) Ketamine is a standard anaesthetic drug that has been studied as a possible treatment for acute suicidal ideation. Aside to the potential psychotropic effects of ketamine, a Cochrane review reported that available studies suggest a modest effect of ketamine for chronic pain months to years after surgical intervention. We present a patient with acute suicidal ideation who required immediate inpatient psychiatric admission in the setting of concurrent chronic pain on cannabinoids which could not be prescribed within our inpatient hospital setting. This presented a clinical dilemma to rapidly reverse the patient’s suicidality while substituting the patient’s prescribed cannabinoid products with an alternative pain regimen. Since there is emerging support in the use of ketamine in suicidality and chronic pain, we administered ketamine while withholding cannabinoid products and found evidence to support its use in rapid reversal of suicidal ideation and temporary chronic pain relief. BMJ Publishing Group 2017-11-12 /pmc/articles/PMC5747796/ /pubmed/29133582 http://dx.doi.org/10.1136/bcr-2017-222059 Text en © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
Bigman, Daniel
Kunaparaju, Sindhura
Bobrin, Bradford
Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
title Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
title_full Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
title_fullStr Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
title_full_unstemmed Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
title_short Use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
title_sort use of ketamine for acute suicidal ideation in a patient with chronic pain on prescribed cannabinoids
topic Novel Treatment (New Drug/Intervention; Established Drug/Procedure in New Situation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747796/
https://www.ncbi.nlm.nih.gov/pubmed/29133582
http://dx.doi.org/10.1136/bcr-2017-222059
work_keys_str_mv AT bigmandaniel useofketamineforacutesuicidalideationinapatientwithchronicpainonprescribedcannabinoids
AT kunaparajusindhura useofketamineforacutesuicidalideationinapatientwithchronicpainonprescribedcannabinoids
AT bobrinbradford useofketamineforacutesuicidalideationinapatientwithchronicpainonprescribedcannabinoids